Cancer – AOST1321: Phase 2 Study of Denosumab, a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
Condition or Therapy:
Cancer and Blood Disorders
Study Number: AOST1321
What is the goal of this study?
This study looks at how well patients with recurrent or refractory osteosarcoma react to denosumab.
Who can join the study?
This study may be a good fit for children and young adults who:
- are between 11 and 49 years old and
- have relapsed or refractory osteosarcoma.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.